- Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 -
More:
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
Related Post
- Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 - May 6th, 2025
- ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - May 6th, 2025
- uniQure to Announce First Quarter 2025 Financial Results - May 6th, 2025
- Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights - May 6th, 2025
- Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 - May 6th, 2025
- FibroGen to Report First Quarter 2025 Financial Results - May 6th, 2025
- Context Therapeutics Announces Chief Medical Officer Transition - May 6th, 2025
- Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates - May 6th, 2025
- Certara Reports First Quarter 2025 Financial Results - May 6th, 2025
- Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update - May 6th, 2025
- DBV Technologies to Participate in the Citizens JMP Life Sciences Conference - May 6th, 2025
- Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company - May 6th, 2025
- Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET - May 6th, 2025
- Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of... - May 6th, 2025
- Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity - May 6th, 2025
- Novaremed Announces Completion of Enrollment in NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with... - May 6th, 2025
- argenx to Present at BofA Securities 2025 Health Care Conference - May 6th, 2025
- Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation - May 6th, 2025
- Angelini Ventures Co-Leads $45 Million Series B Financing of Nuevocor to Advance Transformative Treatment for Genetic Dilated Cardiomyopathy - May 6th, 2025
- Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025 - April 24th, 2025
- Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 - April 24th, 2025
- Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 - April 24th, 2025
- Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting - April 24th, 2025
- Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses - April 24th, 2025
- Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in... - April 24th, 2025
- Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025 - April 24th, 2025
- Aptose Announces Auditor Not Standing for Re-Appointment - April 24th, 2025
- Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and... - April 24th, 2025
- Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) - April 24th, 2025
- HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 - April 24th, 2025
- Test Your Poison Launches Drug Testing Kits to Improve Public Safety and Address Drug Contamination Risks at Festivals and Nightclubs - April 24th, 2025
- Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025 - April 24th, 2025
- [Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter - April 24th, 2025
- Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea - April 24th, 2025
- Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2... - April 24th, 2025
- Pharming Group to report first quarter 2025 financial results on May 8 - April 24th, 2025
- Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed - April 24th, 2025
- Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients - April 24th, 2025
- Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential... - April 24th, 2025
- NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - February 24th, 2025
- Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial... - February 24th, 2025
- Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million - February 24th, 2025
- Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call - February 24th, 2025
- Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 - February 24th, 2025
- Ensho Therapeutics Announces Presentation of Data Highlighting NSHO-101 as a Once-Daily Oral Agent for the Potential Treatment of Inflammatory Bowel... - February 24th, 2025
- Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration - February 24th, 2025
- Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 - February 24th, 2025
- Dogecoin Cash, Inc. (OTC:CBDS) Announces Strategic Expansion of Crypto Holdings with Acquisition of 420 Million Dogecoin Cash ($DOG) - February 24th, 2025
- Ipsen S.A. publishes its 2024 consolidated financial statements - February 24th, 2025
- Fortrea to Add Erin L. Russell to Board of Directors - February 24th, 2025
- Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned - February 24th, 2025
- Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative... - February 24th, 2025
- eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. - February 24th, 2025
- Dr. Gregory George MD PhD Joins Mesoblast Board - February 24th, 2025
- IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference - February 24th, 2025
- Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease - February 24th, 2025
- OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO - February 24th, 2025
- Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4] - February 24th, 2025
- Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - February 24th, 2025
- Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association... - February 15th, 2025
- ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences - February 15th, 2025
- Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - February 15th, 2025
- Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination - February 15th, 2025
- Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® - February 15th, 2025
- IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - February 15th, 2025
- Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update - February 15th, 2025
- Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 - February 15th, 2025
- Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) - February 15th, 2025
- Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency - February 15th, 2025
- Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity - February 15th, 2025
- Entero Therapeutics Appoints Richard Paolone as CEO - February 15th, 2025
- NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation - February 15th, 2025
- Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 15th, 2025
- Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference - February 15th, 2025
- Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results - February 15th, 2025
- Edesa Biotech Reports Fiscal 1st Quarter 2025 Results - February 15th, 2025
- Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older - February 15th, 2025
- Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision - February 15th, 2025
- PacBio Grants Equity Incentive Award to New Employee - February 15th, 2025
- Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program - February 7th, 2025
Tags: